Table 5 Molecular and antimicrobial resistance features of high MIC and low MIC MRSA isolates
Characteristic | Vancomycin MIC < 2 N = 97 Number of patients (%) | Vancomycin MIC = 2 N = 26 Number of patients (%) | p-value a |
|---|---|---|---|
SCCmec type | Â | Â | Â |
SCCmec II | 24 (24.7) | 2 (7.7) | Â |
SCCmec III | 52 (53.6) | 24 (92.3) | Â |
SCCmec IV | 10 (10.3) | Â | Â |
SCCmec V | 11 (11.3) | Â | Â |
Spa type | Â | Â | Â |
Spa t037 | 50 (51.5) | 22 (84.6) | Â |
Spa t002 | 24 (24.7) | 2 (7.7) | Â |
Spa t437 | 18 (18.6) | 0 (0) | Â |
Spa t298 | 1 (1) | 0 (0) | Â |
Spa t1081 | 1 (1) | 0 (0) | Â |
Spa t138 | 0 (0) | 1 (3.8) | Â |
Non-typeable | 3 (3.1) | 1 (3.8) | Â |
Isolates Susceptibility rate | Â | Â | Â |
Erythromycin | 2 (2.1) | (0) | 0.460 |
Clindamycin | 14 (14.4) | 1 (3.8) | 0.143 |
Tetracycline | 33 (34) | 2 (7.7) | 0.008 |
Levofloxacin | 20 (20.6) | 0 (0) | 0.011 |
TMP/SMZ | 45 (46.4) | 2 (7.7) | < 0.001 |
Gentamicin | 17 (13.4) | 0 (0) | 0.021 |
Rifampin | 78 (80.4) | 16 (61.5) | 0.044 |